SCHEMBL2632070

SCHEMBL2632070

CN(C)CCCC=N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26981411 0.92
SCHEMBL2631782 0.81
SCHEMBL27937461 0.75 ALDH1A1 (0.53)
SCHEMBL22510093 0.74 S1PR2 (0.35)
SCHEMBL23451607 0.73 ALDH1A1 (0.50)
SCHEMBL1613246 0.73
SCHEMBL5370749 0.71
SCHEMBL22418662 0.71
SCHEMBL25613188 0.71
SCHEMBL17941656 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199600-A1 CONDENSED HETEROCYCLIC COMPOUND HAVING A SULFONAMIDE GROUP OR SALT THEREOF, AGRICULTURAL OR HORTICULTURAL INSECTICIDE OR ANIMAL ECTOPARASITE OR ENDOPARASITE CONTROL AGENT COMPRISING THE COMPOUND OR THE SALT THEREOF, AND METHOD FOR USING THE COMPOUND OR THE SALT THEREOF, THE INSECTICIDE, OR THE CONTROL AGENT NIHON NOHYAKU CO., LTD. (JP) 2024-06-20 US disclosed
EP-4303214-A1 FUSED HETEROCYCLE COMPOUND HAVING SULFONAMIDE GROUP OR SALT THEREOF, AGRICULTURAL/HORTICULTURAL PESTICIDE AND EXTERNAL OR INTERNAL PARASITE CONTROLLING AGENT FOR ANIMALS CONTAINING SAID COMPOUND OR SALT THEREOF, AND METHOD OF USE THEREFOR Nihon Nohyaku Co., Ltd. (JP) 2024-01-10 EP disclosed
US-20230058784-A1 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. 2023-02-23 US disclosed
EP-3238738-B1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORP (CA) 2020-09-23 EP disclosed
EP-3238738-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS Arbutus Biopharma Corporation (CA) 2017-11-01 EP disclosed
EP-2355658-B1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORP (CA) 2017-09-27 EP disclosed
US-9764036-B2 Lipids and compositions for the delivery of therapeutics ARBUTUS BIOPHARMA CORPORATION (CA) 2017-09-19 US disclosed
EP-3207944-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS Arbutus Biopharma Corporation (CA) 2017-08-23 EP disclosed
US-9682139-B2 Lipids and compositions for the delivery of therapeutics ARBUTUS BIOPHARMA CORPORATION (CA) 2017-06-20 US disclosed
US-20160317676-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2016-11-03 US disclosed
US-20160213785-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2016-07-28 US disclosed
US-9220683-B2 Lipids and compositions for the delivery of therapeutics TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2015-12-29 US disclosed
US-20150265708-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2015-09-24 US disclosed
US-8999351-B2 Lipids and compositions for the delivery of therapeutics TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2015-04-07 US disclosed
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-17 US disclosed
US-20120095075-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed
US-20120027796-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
WO-2012016184-A2 METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-02-02 WO disclosed
US-20110311583-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2011-12-22 US disclosed
WO-2010054405-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed